Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoviVac Safety and Immunogenicity in Adults 18-60
NCT05046548Phase 2Completed
- Start
- Oct 2020
- Primary completion
- Oct 2020
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of COVI-VAC in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Geometric Mean Titer. Started Oct 2020; status: completed.
02
Drugs
COVI-VAC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05046548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046548.